Test-firing ammunition for spliceosome inhibition in cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24097858.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2461 and PMC identifier 3839097.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy. Clin Cancer Res; 19(22); 6064-6. ©2013 AACR.
Medical subject headings
- Antibiotics, Antineoplastic
- Epoxy Compounds
- Macrolides
- Neoplasms
- Spliceosomes